Search Result

Results for "

166 Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Apoptosis (4) Autophagy (1) Bacterial (2) Bcr-Abl (1) Ceramidase (1) Cholinesterase (ChE) (1) DNA/RNA Synthesis (1) EGFR (2) Endogenous Metabolite (1) Epigenetic Reader Domain (3) FLT3 (1) HDAC (3) Histone Acetyltransferase (1) Histone Methyltransferase (2) Isocitrate Dehydrogenase (IDH) (2) Isotope-Labeled Compounds (1) Necroptosis (1) Parasite (2) Phosphodiesterase (PDE) (6) PI3K (2) RIP kinase (1) SARS-CoV (1) VEGFR (1)
By Research Areas:	Cancer (20) Infection (6) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (4)

By Targets:

ADC Cytotoxin (1)

Apoptosis (4)

Autophagy (1)

Bacterial (2)

Bcr-Abl (1)

Ceramidase (1)

Cholinesterase (ChE) (1)

DNA/RNA Synthesis (1)

EGFR (2)

Endogenous Metabolite (1)

Epigenetic Reader Domain (3)

FLT3 (1)

HDAC (3)

Histone Acetyltransferase (1)

Histone Methyltransferase (2)

Isocitrate Dehydrogenase (IDH) (2)

Isotope-Labeled Compounds (1)

Necroptosis (1)

Parasite (2)

Phosphodiesterase (PDE) (6)

PI3K (2)

RIP kinase (1)

SARS-CoV (1)

VEGFR (1)

By Research Areas:

Cancer (20)

Infection (6)

Inflammation/Immunology (7)

Metabolic Disease (1)

Neurological Disease (4)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: ALCAM/CD166

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117155

PKI-166

EGFR Cancer

PKI-166 is a potent, selective and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC₅₀ of 0.7 nM .

PKI-166	EGFR	Cancer
PKI-166 is a potent, selective and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC₅₀ of 0.7 nM .

HY-135236

OXFBD04	Epigenetic Reader Domain	Cancer
OXFBD04 is a potent and selective BRD4 inhibitor with an IC₅₀ of 166 nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity .

HY-110328

PKI-166 hydrochloride

EGFR Cancer

PKI-166 hydrochloride is a potent, selective and orally active EGFR tyrosine kinase inhibitor, with an IC₅₀ of 0.7 nM .

PKI-166 hydrochloride	EGFR	Cancer
PKI-166 hydrochloride is a potent, selective and orally active EGFR tyrosine kinase inhibitor, with an IC₅₀ of 0.7 nM .

HY-155491

Antibacterial agent 166	Bacterial	Cancer
Antibacterial agent 166 (Compound 19q), a derivative of Nitisinone (HY-B0607), is a selective and orally active *Fusobacterium nucleatum* inhibitor with a MIC₅₀ of 1 μg/mL. Antibacterial agent 166 effectively attenuates the migratory ability of MC-38 cells induced by Fusobacterium nucleatum. Antibacterial agent 166 is a promising anti-F. nucleatum lead compound and can be used for colorectal cancer (CRC) research .

HY-139619

LT-850-166

FLT3 Cancer

LT-850-166 is a potent FLT3 inhibitor with the capacity of overcoming a variety of FLT3 mutations.
HY-135880

OMDM-3

Endogenous Metabolite Neurological Disease

OMDM-3 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 16.6 μM .

LT-850-166	FLT3	Cancer
LT-850-166 is a potent FLT3 inhibitor with the capacity of overcoming a variety of FLT3 mutations.

OMDM-3	Endogenous Metabolite	Neurological Disease
OMDM-3 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 16.6 μM .

HY-15180

Buparlisib Hydrochloride Maximum Cited Publications 62 Publications Verification BKM120 Hydrochloride; NVP-BKM120 Hydrochloride	PI3K Apoptosis	Cancer
Buparlisib Hydrochloride (BKM120 Hydrochloride) is a pan-class I PI3K inhibitor, with IC₅₀ of 52 nM/166 nM/116 nM/262 nM for p110α/p110β/p110δ/p110γ, respectively.

HY-119254

BAY-850 4 Publications Verification	Epigenetic Reader Domain	Metabolic Disease
BAY-850 is a potent and isoform selective ATPase family AAA domain-containing protein 2 (ATAD2) inhibitor, with an IC₅₀ of 166 nM.

HY-B0763

Ibudilast 5 Publications Verification KC-404; AV-411; MN-166	Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .

HY-16934

ML352	Cholinesterase (ChE)	Neurological Disease
ML352 is a noncompetitive inhibitor of the presynaptic choline transporter (CHT) with K_i values of 92 and 166 nM for HEK293 cells expressing human CHT and mouse forebrain synaptosomes, respectively .

HY-B0763S1

Ibudilast-d7	Isotope-Labeled Compounds Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
Ibudilast-d₇ is the deuterium labeled Ibudilast. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia[1].

HY-162371

NRPSs-IN-1	Others	Infection
NRPSs-IN-1 (Compound 7) is a cell-penetrating inhibitor of non-ribosomal peptide synthetase (NRPSs). NRPSs-IN-1 K inhibits gramicidin S synthetase A (GrsA) with a K_d value of 16.6 nM .

HY-18717

Mutant IDH1-IN-2 2 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.

HY-106215

Etiprednol dicloacetate BNP 166; Etiprednol dichloroacetate	Others	Inflammation/Immunology
Etiprednol dicloacetate (BNP 166) is an anti-inflammatory agent. Etiprednol dicloacetate inhibits eosinophil accumulation. Etiprednol dicloacetate can be used in the research of inflammatory airway diseases, such as asthma .

HY-B0763R

Ibudilast (Standard)	Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
Ibudilast (Standard) is the analytical standard of Ibudilast. This product is intended for research and analytical applications. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .

HY-B0763S2

Ibudilast-d7-1 KC-404-d₇-1; AV-411-d₇-1; MN-166-d₇-1	Phosphodiesterase (PDE)
Ibudilast-d₇-1 is the deuterium labeled Ibudilast[1]. Ibudilast (KC-404;AV-411;MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia[2].

HY-146539

HDAC-IN-35

HDAC VEGFR Cancer

HDAC-IN-35 (Compound 14) is a potent, selective HDAC and VEGFR-2 inhibitor, with IC₅₀ values of 0.166 and 13.2 µM for HDAC6 and VEGFR-2, respectively .

HDAC-IN-35	HDAC VEGFR	Cancer
HDAC-IN-35 (Compound 14) is a potent, selective HDAC and VEGFR-2 inhibitor, with IC₅₀ values of 0.166 and 13.2 µM for HDAC6 and VEGFR-2, respectively .

HY-19540

GSK864 4 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
GSK864 is an isocitrate dehydrogenase 1 (IDH1) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC₅₀ values of 8.8, 15.2 and 16.6 nM.

HY-141866

Acid Ceramidase-IN-1	Ceramidase	Neurological Disease
Acid Ceramidase-IN-1 is a potent and oral bioavailable acid ceramidase (AC, ASAH-1) inhibitor (hAC *IC₅₀*=0.166 μM). Acid Ceramidase-IN-1 has excellent brain penetration in mice .

HY-70063

Buparlisib Maximum Cited Publications 62 Publications Verification BKM120; NVP-BKM120	PI3K Apoptosis	Cancer
Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC₅₀s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.

HY-155648

*Tuberculosis inhibitor* 6**	Bacterial	Infection
Tuberculosis inhibitor 6 (compound 2c) is a 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivative that shows highly active against Mycobacterium tuberculosis (MIC₉₀ of ≤1.66 μM) and Mycobacterium marinum (MIC₉₀ of 2.65 μM) .

HY-100131

GSK481	RIP kinase	Inflammation/Immunology
GSK481 is a highly potent, selective, and specific receptor interacting protein 1 (RIP1) kinase inhibitor with an IC₅₀ of 1.3 nM, which inhibits Ser ¹⁶⁶ phosphorylation in wild-type human RIP1 (IC₅₀=2.8 nM). GSK481 also exhibits excellent translation in the U937 cellular assay with an IC₅₀ of 10 nM .

HY-162377

HDAC-IN-70	HDAC Apoptosis Necroptosis	Cancer
HDAC-IN-70 (compound 4c) is HDAC6 inhibitor with the IC₅₀ values of 64.13 nM, 166 nM, 618 nM and 253 nM for HDAC6, HDAC1, HDAC2 and HDAC4, respectively. HDAC-IN-70 induces cell cycle arrest, apoptosis and necrotic. HDAC-IN-70 can be used for study of leukemia .

HY-148396

*UCK2 Inhibitor-3*	DNA/RNA Synthesis	Infection Cancer
UCK2 Inhibitor-3 is a non-competitive inhibitor of uridine-cytidine kinase 2 (UCK2, a pyrimidine salvage enzyme) with an IC₅₀ value of 16.6 μM. UCK2 can replace dihydroorotate dehydrogenase (DHODH), in a certain extent, in infected or rapidly dividing cells to continue efficient uridine salvage. UCK2 Inhibitor-3 also inhibits DNA polymerase eta and kappa with IC₅₀s of 56 μM and 16 μM .

HY-12164

Mocetinostat 10+ Cited Publications MGCD0103	HDAC Autophagy Apoptosis	Cancer
Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC₅₀s of 0.15, 0.29, 1.66 and 0.59 μM for HDAC1, HDAC2, HDAC3 and HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.

HY-79256

MMAF-OMe 1 Publications Verification Monomethyl auristatin F methyl ester	ADC Cytotoxin	Cancer
MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC₅₀s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 ^-) cell lines, respectively.

HY-W348072

SARS-CoV-2-IN-59	SARS-CoV	Infection
SARS-CoV-2-IN-59 (compound E07), an imidazoline derivative, is a non-peptide small molecule inhibitor of SARS-CoV-2 that targets the main protease (Mpro) of the coronavirus. SARS-CoV-2-IN-59 has a strong interaction with residues on Mpro (Met 165, Gln 166, Met 165, His 41, Gln 189) .

HY-163189

c-ABL-IN-6	Bcr-Abl	Neurological Disease
c-ABL-IN-6 (compound A6) is a c-ABL inhibitor with IC₅₀ value of 16.6 nM. c-ABL-IN-6 displays higher neuroprotective effects against SH-SY5Y cell death induced by MPP ⁺ (HY-W008719). c-ABL-IN-6 can be used for the research of neurodegenerative disorder .

HY-132197

CBP/p300-IN-12	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC₅₀ of 166 nM) and CBP inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC₅₀ of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450 .

HY-110137A

Furamidine DB75; NSC 305831	Histone Methyltransferase Phosphodiesterase (PDE) Parasite	Infection Inflammation/Immunology Cancer
Furamidine (DB75) is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC₅₀ of 9.4 μM. Furamidine is selective for PRMT1 over PRMT5, PRMT6, and PRMT4 (CARM1) (IC₅₀s of 166 µM, 283 µM, and >400 µM, respectively). Furamidine is a potent, reversible and competitive tyrosyl-DNA phosphodiesterase 1 (TDP-1) inhibitor. Inhibition of TDP-1 by Furamidine is effective both with single- and double-stranded DNA substrates but is slightly stronger with the duplex DNA. Furamidine is also an antiparasite agent .

HY-110137

Furamidine dihydrochloride 1 Publications Verification DB75 dihydrochloride; NSC 305831 dihydrochloride	Histone Methyltransferase Phosphodiesterase (PDE) Parasite	Infection Inflammation/Immunology Cancer
Furamidine dihydrochloride (DB75 dihydrochloride) is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC₅₀ of 9.4 μM. Furamidine dihydrochloride is selective for PRMT1 over PRMT5, PRMT6, and PRMT4 (CARM1) (IC₅₀s of 166 µM, 283 µM, and >400 µM, respectively). Furamidine dihydrochloride is a potent, reversible and competitive tyrosyl-DNA phosphodiesterase 1 (TDP-1) inhibitor. Inhibition of TDP-1 by Furamidine dihydrochloride is effective both with single- and double-stranded DNA substrates but is slightly stronger with the duplex DNA. Furamidine dihydrochloride is also an antiparasite agent .

Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166)	Inhibitory Antibodies	Others
Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human Mac-2/Galectin-3.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-135880

OMDM-3	Structural Classification Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
OMDM-3 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 16.6 μM .

Cat. No.	Product Name	Chemical Structure

HY-B0763S1

Ibudilast-d7
Ibudilast-d₇ is the deuterium labeled Ibudilast. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia[1].

Ibudilast-d7

Ibudilast-d₇ is the deuterium labeled Ibudilast. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia[1].

HY-B0763S2

Ibudilast-d7-1
Ibudilast-d₇-1 is the deuterium labeled Ibudilast[1]. Ibudilast (KC-404;AV-411;MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia[2].

Ibudilast-d7-1

Ibudilast-d₇-1 is the deuterium labeled Ibudilast[1]. Ibudilast (KC-404;AV-411;MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks